Kamada (KMDA) Change in Receivables (2012 - 2026)
Kamada's (KMDA) quarterly Change in Receivables came in at -$191000.0 in Q2 2026, up 90.96% on a YoY basis from -$100020.6 in Q2 2025, and up 98.04% quarter-over-quarter from -$9.8 million in Q1 2026.
Analysis
Kamada (KMDA) Change in Receivables (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Change in Receivables for 15 consecutive years, with -$191000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Change in Receivables rose 90.96% year-over-year to -$191000.0; the trailing twelve-month figure through Jun 2026 stood at -$6.7 million (down 71.76% YoY), and the FY2025 full-year result was -$5.4 million, down 173.5% from the prior year.
- Change in Receivables grew to -$191000.0 in Q2 2026 per KMDA's latest filing, from -$9.8 million in the prior quarter.
- Across five years, Change in Receivables topped out at $10.0 million in Q3 2024 and bottomed at -$9.8 million in Q1 2026.
- Historically, Change in Receivables has averaged -$611666.7 across 5 years, with a median of -$404500.0 in 2023.
- The widest YoY moves for Change in Receivables: up 1718.77% in 2024, down 4261.02% in 2024.
- Over 5 years, Change in Receivables stood at -$3.1 million in 2022, then surged by 283.29% to $5.8 million in 2023, then sank by 190.78% to -$5.2 million in 2024, then jumped by 182.24% to $4.3 million in 2025, then tumbled by 104.44% to -$191000.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$191000.0, -$9.8 million, and $4.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1.09 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 333.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 140.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 838.50 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -53.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 269.40 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | -191,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -191,000.00 |
| Mar 31, 2026 | -9.76 Mn |
| Dec 31, 2025 | 4.30 Mn |
| Sep 30, 2025 | -1.04 Mn |
| Jun 30, 2025 | -2.11 Mn |
| Mar 31, 2025 | -6.56 Mn |
| Dec 31, 2024 | -5.23 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Jun 30, 2024 | -7.37 Mn |
| Mar 31, 2024 | 610,000.00 |
| Dec 31, 2023 | 5.76 Mn |
| Sep 30, 2023 | -618,000.00 |
| Jun 30, 2023 | 177,000.00 |
| Mar 31, 2023 | 6.31 Mn |
| Dec 31, 2022 | -3.14 Mn |
| Sep 30, 2022 | -6.36 Mn |
| Jun 30, 2022 | 3.61 Mn |
| Mar 31, 2022 | 589,000.00 |
| Dec 31, 2021 | -8.42 Mn |
| Sep 30, 2021 | 1.20 Mn |